medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2012, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2012; 28 (4)

High-dose dexamethasone in chronic primary immune thrombocytopenia

Roque-García W, Almagro-Vázquez D, Castillo-González D, Agramonte-Llanes O

Language: Spanish
References: 40
Page: 404-415
PDF size: 200.01 Kb.


ABSTRACT

A prospective, analytical and applied study was conducted to determine the effectiveness of treatment with high-dose dexamethasone in patients with chronic primary immune thrombocytopenia, who were assisted at the Hemostasis service of the Institute of Hematology and Immunology from April 2008 to April 2011. 30 patients, 18 females and 12 males with an average age of 37 years were studied. Favorable response was achieved in 17 patients (68.0%), out of them, 14 had complete and 3 had partial remission respectively. No response was obtained in eight patients. A significant increase in platelet count was observed during the whole therapy. Referrals are obtained early, from the first to the third cycle, and late responses were not observed. Most patients who responded to previous treatment with prednisone had a favorable response to dexamethasone. In general, adverse events were mild and the most frequent were myalgia, edema, and arthralgias. Three patients required stopping the treatment because of side effects and nine maintained remission during the follow-up period. High-dose dexamethasone is an effective and safe alternative treatment in patients with chronic primary immune thrombocytopenia.


REFERENCES

  1. Cooper N, Bussel J. The pathogenesis of immune thrombocytopenic purpura. Br J Haematol. 2006 May;133(4):364-74.

  2. Chu WY, Korb J, Sakamoto MK. Idiopathic thrombocytopenic purpura. Pediatr Rev. 2000;21:95-103.

  3. British Committee for Standards in Haematology. Guidelines for the investigations and management of idiopathic thrombocytopenic purpura in adults, children and pregnancy. Br J Haematol. 2003 Feb;120(4):574-96.

  4. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adults patients with idiopathic thrombocytopenic purpura: a systematic literature review to assess long term platelet count responses, prediction of response and surgical complications. Blood. 2004 Nov;104(9):2623-34.

  5. Mc Millan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med. 1997 Feb;126(4):307-14.

  6. Blanchette V, Imbach P, Andrew M. Randomized trial of intravenous inmunoglobulin G, intravenous anti D and oral Prednisona in childhood thrombocytopenic purpura. Lancet. 1994 Sep;344(8924):703-7.

  7. Ambriz R, Muñoz R, Pizzuto J, Quintanar E, Morales M, Avilés A. Low dose autologus in vitro opsonized erithrocytes for refractory autoimmnune thrombocytopenic purpura in adults. Arch Intern Med. 1987 Jan;147(1):101-8.

  8. Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adults patients with idiopathic thrombocytopenic purpura after failure of splenectomy. A systematic review. Ann Int Med. 2004 Jan;140(2):112-20.

  9. Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric trial of the Cooperative Latin America Group on Hemostasis and Thrombosis. Blood. 1984 Dec;64(6):1179-83.

  10. Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med. 1983 Jun;308(23):1396-9.

  11. Almagro D, Crespo O, González X, Espinosa E. Dosis intermedias de Danazol en la púrpura trombocitopénica idiomática crónica. Rev Iberoamer Tromb Hemostasia. 1996;9:19-21.

  12. Mc Verry BA, Auger M, Bellingham AJ. The use of Danazol in the management of chronic immune thrombocytopenic purpura. Br J Haematol. 1985 Sept;161(1):145-8.

  13. Proctor SJ. Alpha interferon therapy in the treatment of idiopathic thrombocytopenic purpura. Eur J Cancer. 1991;27(suppl):S63-8.

  14. Dikici B, Bosnak M, Kara IH, Dogru O, Alkaya A, Hasolat K. Interferon treatment of refractory idiopathic thrombocytopenic purpura. Pediatr Int. 2001 Dec;43(6):577-80.

  15. Almagro D, Hernández P, López Saura P, Perea S, Apestegui I. Interferón-alfa recombinante en el tratamiento de la púrpura trombocitopénica idiopática crónica. Rev Iberoamer Tromb Hemost. 1990;3:39-41.

  16. Sibilia J, Sordet C. Rituximab: a original biotherapy in autoimmune disorders. Rev Med Interne. 2005;26(6):485-500.

  17. Semple JW. ITP Three RS: regulation routing, Rituximab. Blood. 2008;112(4):927-8.

  18. Taube J, Schmid H, Reinhard H, von Stackelberg A, Overbeg VS. Effect of a single dose of Rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica. 2005;90:281-3.

  19. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigovin C. Systematic review: Efficacy and safety of Rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25-33.

  20. Bussel JB, Kuter DJ, George JN, Mc Millan R, Aledort LM, Coklin CT. AMG 531, a thrombopoiesis-stimulating protein for chronic ITP. New Engl J Med. 2006;355(16):1672-81.

  21. Kuter DJ. New thrombopoietic growth factors. Blood. 2007 Jun;109(11):4607-16.

  22. Vicente V, Pérez-Andreu V, Rivera-Lozano ML. Análogos de la trombopoyetina en púrpura trombocitopénica inmune. Haematologica. 2008;93;434-9.

  23. Andersen JC. Response to resistant idiopathic thrombocytopenic purpura to pulsed high dose Dexamethasone treatment. N Eng J Med. 1994;330:1560-4.

  24. Dubbeld P, Van der Heul C, Hillen HF. Effect of high dose Dexamethasone in Prednisone-resistant autoinmune thrombocytopenic purpura. Neth J Med. 1991;39(1-2):6-10.

  25. Arruda VR, Annichino-Bizzacchi JM. High-dose Dexamethasone therapy in chronic idiopathic thrombocytopenic purpura. Ann Hematol. 1996;73(4):175-7.

  26. Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: A prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122(6):966-74.

  27. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocitopenic purpura in adults increases with age. Blood.1999;94(3):909-13.

  28. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97(9):2549-54.

  29. Mc Farland J. Pathophysiology of platelet destruction in immune (idiopathic) thrombocytopenic purpura. Blood Rev. 2002;16:1-2.

  30. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 2004;79(4):504-22.

  31. Caulier MT, Rose C, Roussel MT, Huart C, Bauters F, Fenaux P. Pulsed high-dose Dexamethasone in refractory chronic idiopathic thrombocytopenic purpura: a report on 10 cases. Br J Haematol. 1995;91(2):477-9.

  32. Tsiara S, Kaiafas P, Kapsali H, Christou L, Bourantas KL. Pulsed high - dose Dexamethasone therapy in patients with chronic refractory idiopathic thrombocytopenic purpura. Haemato. 1998;1:48-51.

  33. Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol. 2004 Dec;83(12):764-8.

  34. Mazzuconi MG, Fazi P, Bernasconi S, De Rossi G, Leone Gi, Gugliotta L, et al. Therapy with high dose Dexametasone in previously untrated patients affected by idiopathic thrompocytopenic purpura: a GIMEMA experience. Blood. 2007 Feb;109(4):1401-7.

  35. Li H, Zhang L, Zhao H, Ji L, Yang R. Chronic idiopathic thrombocytopenic purpura in Chinese patients: a retrospective single centered analysis of 1791 cases. Chin Med J (Engl). 2005 Jan;118(1):34-7.

  36. Lacey JV, Penner JA. Managmement of immune thrombocytopenic purpura in the adult. Semin Thromb Hemost. 1977 Jan;3(3):160-74.

  37. Cohen YC, Djulbegovic B, Sharnai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000 Jun;160(11):1630-8.

  38. Cortelazzo S, Finazzi G, Buelli M. High risk of severe bleeding in aged patients with chronic thrombocytopenic purpura. Blood 1991 Jan;77(1):31-3.

  39. Bae SH, Lee J-H. High dose Dexamethasone vs. conventional dose Prednisolone in adult ITP. Clinical Trial. NCT00451594. Disponible en: http://clinicaltrials.gov/ct2/show/NCT00451594

  40. Ming Hou, DR. High-dose Dexamethasone and conventional dose Prednisone, for the first-line treatment of adults with ITP: a multicenter, randomized controlled, Clinical Trial. NCT01356511. Disponible en: http://clinicaltrials.gov/ct2/results?term=NCT01356511




2020     |     www.medigraphic.com